Home Research Training Publications Media Contact


10v and 13v PCV study

Given the importance of pneumonia as a cause of childhood mortality, and the role Streptococcus pneumoniae plays in the aetiology of pneumonia (and meningitis), interventions are desperately needed to decrease the burden of invasive pneumococcal disease. The introduction of a pneumococcal vaccine to the routine vaccination schedule is one way of reducing the burden of disease. Currently, there are two conjugate vaccines on the market and one polysaccharide vaccine. The conjugate vaccines generally produce a better immune response in young children, however they are more expensive and do not offer the same broad coverage that the 23 valent polysaccharide vaccine does. More information is required to determine which vaccine, or whether a combination of the conjugate vaccine and the polysaccharide vaccine, should be introduced to PNG.

The study aims to evaluate the safety and immunogenicity of the 10 valent and 13 valent pneumococcal conjugate vaccines when given in an accelerated schedule (1, 2, 3 months) in children in PNG; and to determine the response to a booster dose of the 23 valent polysaccharide vaccine given at 9 months.
This work is funded through a grant from Exxon Mobil Limited. The study began in 2011 and will be completed in early 2013.
It is being conducted in the Asaro Valley, Eastern Highlands Province, by both the Immunology and Bacteriology sections at PNGIMR in collaboration with experts from the National Department of Health, University of Papua New Guinea, Telethon Institute of Child Health Research and University of Western Australia.


Infection and Immunity



Dr William Pomat
Deputy Director - Science and Unit Head

This website contains public information about our work. If you wish to reproduce our material, acknowledge the Papua New Guinea Institute of Medical Research as your source and contact us where appropriate.